Back to search

Peptide record

TPDB18938

SHIVA 10 AC Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB18938
SHIVA 10 AC
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF Antifungipept CAFPdb PD_Hemolysis
standard
No
A 23-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, AntiCP 2.0, CancerPPD 2.0, and other sources, with an available 3D structural model.
Sequence
FAKKLAKKLKKLAKKLAKLALAL
Physicochemical Analysis
C123H226N32O24
RNDCEQGHIMPSTWYV
K
2537.35
11.41
9
0
14
+9
2.84
0.222
144.78
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
6
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
7
L
9
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 6 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 7 K: 9 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
23
C123H226N32O24
2537.35
11.41
+9
2.84
0.222
Free
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 10 records
Evidence 1 Activity

Activity

LD50
LD50 =>1000 µg/ml
Anticancer
>1000 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

Not Available
Anticancer

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

Not Available
Anticancer

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =>1000 µg/ml
Anticancer
>1000 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =83 µg/ml
Anticancer
83 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =>1000 µg/ml
Anticancer
>1000 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
76 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 76 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 8 Activity

Activity

LD50
Toxicity
57 µg/mL
Cytotoxic
LD50 | 57 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 9 Activity

Activity

50% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 50 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 10 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis